Experience With 68 Girls With Turners Syndrome and Evaluation of Final Height in 26 Patients Treated With Growth Hormone in Combination or Without Oxandrolone

Short stature is a common feature in S Turner s syndrome; (TS) final height inuntreated patients is on average 20cmbelow the population mean for adultwomen. When recombinant growthhormone (GH) became available, supraphysiologicGH doses with or without oxandrolone(OX) were administrated in order to improvegrowth in patients wih TS in several studiesObjective: The objective of this study was toPuberty was induced at a mean age of 14.5 years.Results: There was a marked difference in groupGH ± OX cumulative growth during 4.3 years oftherapy in comparison with untreated TS patients.Twenty-six patients are now near or at finalheight: Group GH (n=I7), mean final heightwas 148.7 em (PAH 142.1 em, gain 6.6 em); groupGH+ OX (n = 9), 151.9 em (PAH, 141.5 em, gain9.4 em). In the untreated group (n = 33), mean finalheight was 139.1 em. Cumulative growth wasmore significant in GH plus OX than GH alonetreated subjects (P 0.001).Conclusion: The diagnosis of TS is often delayedin our country and this defers the timely and appropriatetreatment of short stature. Our resultsare in keeping with stu dies demonstrating moderatedoses of GH plus OX and late induction ofpuberty are able to improve final height even inpatients with TS, treated relatively late.